Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7
- PMID: 17644749
- DOI: 10.1182/blood-2007-03-080630
Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7
Comment in
-
Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7.Blood. 2009 Mar 19;113(12):2867-8. doi: 10.1182/blood-2008-12-195693. Blood. 2009. PMID: 19299654 No abstract available.
Comment on
-
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.Blood. 2007 Jan 1;109(1):52-7. doi: 10.1182/blood-2006-05-021162. Epub 2006 Aug 1. Blood. 2007. PMID: 16882708 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical

